Imagyn seeking to enjoin ABBI manufacturing and sales in Oct. 16 suit against USSC.
This article was originally published in The Gray Sheet
IMAGYN SEEKS TO ENJOIN USSC MANUFACTURING AND U.S. SALES OF ABBI minimally invasive breast biopsy device in a suit filed Oct. 16 in Alexandria, Virginia Federal Court. Imagyn Medical Technologies, formally Urohealth Systems, claims that U.S. Surgical Corp.'s ABBI device infringes two patents held by Imagyn related to its Siteselect percutaneous excissional breast biopsy (PEBB) system. Imagyn submitted a 510(k) for Siteselect on June 20; the firm expects to launch the device in February 1998.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.